Ono Pharmaceutical Co., Ltd. (OPHLY)
OPHLY Stock Price Chart
Explore Ono Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze OPHLY price movements and trends.
OPHLY Company Profile
Discover essential business fundamentals and corporate details for Ono Pharmaceutical Co., Ltd. (OPHLY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
2 Oct 2012
Employees
3.85K
Website
https://www.ono-pharma.comCEO
Gyo Sagara
Description
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
OPHLY Financial Timeline
Browse a chronological timeline of Ono Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 29 Oct 2025
Earnings released on 1 Aug 2025
EPS came in at $0.08 falling short of the estimated $0.11 by -25.33%, while revenue for the quarter reached $861.18M , beating expectations by +4.80%.
Earnings released on 8 May 2025
EPS came in at -$0.10 falling short of the estimated $0.03 by -429.66%, while revenue for the quarter reached $772.24M , missing expectations by -5.73%.
Earnings released on 3 Feb 2025
EPS came in at $0.07 falling short of the estimated $0.09 by -23.48%, while revenue for the quarter reached $867.16M , beating expectations by +2.60%.
Earnings released on 31 Oct 2024
EPS came in at $0.08 falling short of the estimated $0.11 by -30.85%, while revenue for the quarter reached $805.28M , missing expectations by -4.59%.
Dividend declared on 30 Sept 2024
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 17 Dec 2024.
Earnings released on 31 Jul 2024
EPS came in at $0.33 surpassing the estimated $0.11 by +187.31%, while revenue for the quarter reached $732.64M , beating expectations by +2.20%.
Earnings released on 9 May 2024
EPS came in at $0.08 falling short of the estimated $0.11 by -28.64%, while revenue for the quarter reached $743.37M , missing expectations by -5.46%.
Dividend declared on 27 Mar 2024
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 8 Jul 2024.
Earnings released on 22 Feb 2024
EPS came in at $0.18 surpassing the estimated $0.16 by +9.79%, while revenue for the quarter reached $937.79M , beating expectations by +11.10%.
Earnings released on 30 Sept 2023
EPS came in at $0.20 falling short of the estimated $0.22 by -10.06%, while revenue for the quarter reached $928.11M , beating expectations by +6.83%.
Dividend declared on 28 Sept 2023
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 18 Dec 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.15 falling short of the estimated $0.17 by -9.95%, while revenue for the quarter reached $830.45M , missing expectations by -2.60%.
Earnings released on 31 Mar 2023
EPS came in at $0.09 falling short of the estimated $0.11 by -18.60%, while revenue for the quarter reached $816.34M , missing expectations by -0.70%.
Dividend declared on 30 Mar 2023
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 10 Jul 2023.
Earnings released on 31 Dec 2022
EPS came in at $0.18 falling short of the estimated $0.18 by -4.42%, while revenue for the quarter reached $943.00M , beating expectations by +2.24%.
Earnings released on 30 Sept 2022
EPS came in at $0.16 surpassing the estimated $0.15 by +0.52%, while revenue for the quarter reached $760.61M , missing expectations by -15.29%.
Dividend declared on 29 Sept 2022
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 16 Dec 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.15 falling short of the estimated $0.15 by -3.14%, while revenue for the quarter reached $785.17M , beating expectations by +0.20%.
Earnings released on 31 Mar 2022
EPS came in at $0.09 falling short of the estimated $0.13 by -30.71%, while revenue for the quarter reached $735.46M , missing expectations by -7.08%.
Dividend declared on 29 Mar 2022
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 11 Jul 2022.
Earnings released on 31 Dec 2021
EPS came in at $0.11 , while revenue for the quarter reached $846.41M .
Earnings released on 30 Sept 2021
EPS came in at $0.13 surpassing the estimated $0.10 by +35.48%, while revenue for the quarter reached $778.49M , missing expectations by -1.89%.
Dividend declared on 28 Sept 2021
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 16 Dec 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.14 , while revenue for the quarter reached $786.06M .
Earnings released on 31 Mar 2021
EPS came in at $0.05 , while revenue for the quarter reached $672.64M .
Dividend declared on 29 Mar 2021
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 6 Jul 2021.
Earnings released on 31 Dec 2020
EPS came in at $0.17 , while revenue for the quarter reached $817.35M .
Earnings released on 30 Sept 2020
EPS came in at $0.12 , while revenue for the quarter reached $715.81M .
Dividend declared on 28 Sept 2020
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 16 Dec 2020.
OPHLY Stock Performance
Access detailed OPHLY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.